Astria Therapeutics (NASDAQ:ATXS) Shares Down 5.3% – Time to Sell?

Astria Therapeutics, Inc. (NASDAQ:ATXS) fell 5.3% on Friday . The stock traded as low as $9.55 and last traded at $9.56. Approximately 41,906 shares were traded during mid-day trading, a decline of 93% from the average session volume of 612,849 shares. The stock had previously closed at $10.09.

Wall Street Analysts Forecast Growth

ATXS has been the subject of a number of research analyst reports. TD Cowen started coverage on shares of Astria Therapeutics in a research report on Monday, July 29th. They set a “buy” rating and a $35.00 target price for the company. Wedbush reissued an “outperform” rating and issued a $22.00 target price on shares of Astria Therapeutics in a research report on Tuesday, August 13th. HC Wainwright reissued a “buy” rating and set a $16.00 price target on shares of Astria Therapeutics in a research report on Thursday. Evercore ISI raised shares of Astria Therapeutics to a “strong-buy” rating in a report on Wednesday, August 14th. Finally, Oppenheimer upped their price objective on Astria Therapeutics from $26.00 to $28.00 and gave the stock an “outperform” rating in a research note on Thursday. Five investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $25.60.

Astria Therapeutics Stock Performance

The firm has a 50 day simple moving average of $11.44 and a two-hundred day simple moving average of $10.60. The stock has a market cap of $523.58 million, a P/E ratio of -4.39 and a beta of 0.71.

Astria Therapeutics (NASDAQ:ATXS) last posted its quarterly earnings data on Monday, August 12th. The biotechnology company reported ($0.43) earnings per share for the quarter, missing the consensus estimate of ($0.38) by ($0.05). As a group, equities research analysts predict that Astria Therapeutics, Inc. will post -1.68 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the company. FMR LLC raised its position in shares of Astria Therapeutics by 29.2% during the third quarter. FMR LLC now owns 7,822,275 shares of the biotechnology company’s stock valued at $86,123,000 after buying an additional 1,767,714 shares during the last quarter. RA Capital Management L.P. acquired a new position in shares of Astria Therapeutics in the 1st quarter worth approximately $62,115,000. Vestal Point Capital LP increased its stake in shares of Astria Therapeutics by 23.1% in the third quarter. Vestal Point Capital LP now owns 4,000,000 shares of the biotechnology company’s stock valued at $44,040,000 after buying an additional 750,000 shares in the last quarter. Vanguard Group Inc. raised its stake in shares of Astria Therapeutics by 23.4% in the first quarter. Vanguard Group Inc. now owns 2,535,891 shares of the biotechnology company’s stock worth $35,693,000 after acquiring an additional 480,184 shares during the last quarter. Finally, Millennium Management LLC lifted its holdings in Astria Therapeutics by 13.5% during the 2nd quarter. Millennium Management LLC now owns 1,842,063 shares of the biotechnology company’s stock worth $16,763,000 after buying an additional 218,518 shares in the last quarter. Institutional investors and hedge funds own 98.98% of the company’s stock.

About Astria Therapeutics

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.